Amgen is the latest big company to cut its workforce, with a recent restructuring that led to about 300 layoffs, the Thousand Oaks-based biotech company said Monday. Amgen has about 24,000 ...
The Federal Trade Commission said the deal would enable Amgen to exploit its size to block ... forced merging pharmaceutical companies to sell off drugs that treat the same types of diseases ...
The Federal Trade Commission sued to block Amgen's $27.8 billion acquisition of Horizon Therapeutics. The FTC argued that the proposed deal would stifle drug competition in the pharmaceutical ...
The FTC wants to block Amgen's acquisition of Horizon even though the two companies' products don't overlap. The agency thinks that Amgen could try to bundle Horizon's products in a way that ...
An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/ May 18 (Reuters) - Amgen Inc (AMGN.O) has agreed not to quickly close ...
An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/ May 15 (Reuters) - The U.S. Federal Trade Commission is expected to ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report) and Natera ...
Shares of Salesforce and Amgen are trading lower Thursday morning, dragging the Dow Jones Industrial Average into negative territory. Shares of ...
Journal Editorial Report: The week's best and worst from Kim Strassel, Jason Riley and Dan Henninger. Images: Bay Area News Group/AP/Zuma Press/iStock Photo Composite: Mark Kelly Try though she ha ...
Bloomberg Intelligence Senior Litigation Analyst, Jennifer Rie and Bloomberg Antitrust Reporter Leah Nylen discuss the latest with the FTC's suit to block Amgen's deal with Horizon Therapeutics.
DULUTH — Maurices recently laid off 24 employees in its corporate offices and field leadership positions. The reduction in force was announced April 18. The cut represents 5% of the company's ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
